Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
No Thumbnail Available
Identifiers
Date
2018-10-01
Authors
Sequist, L.
Gray, J.
Harb, W.
Doebele, R.
Modiano, M.
Jackman, D.
Baggstrom, M.
Atmaca, A.
Felip, E.
Provencio, M.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
biomarker, Seribantumab, Heregulin